IDEXX Expands Catalyst and SediVue Platforms
Idexx has announced improvements to 2 of its chemistry analyzers.
Idexx announced this week that it has expanded its Catalyst diagnostic menu and broadened the medical utility of its SediVue analyzer.
Point-of-Care Progesterone Test
Idexx has added a new canine progesterone test to its Catalyst Dx and Catalyst One chemistry analyzers. This in-house test measures progesterone levels to determine ovulation status in potentially breedable dogs.
According to a company press release, about 25% of US veterinary hospitals provide reproductive management services. “IDEXX's new real-time progesterone testing option gives me an actual numeric result versus a range—and provides results right away during the visit—enabling me to pinpoint ovulation and achieve the best outcome for my breeder clients,” said Michigan practice owner John F. Wilson, DVM, DABVP.
The product is expected to ship by the end of March.
Updated software just released for the SediVue Dx Urine Sediment Analyzer expands the product’s ability to assess liver function and blood disorders in critical care patients. It also produces more detailed images in some situations that enable more accurate identification of sediment in even the most complex samples.
“Urine sediment analysis is an important part of a patient’s minimum diagnostic workup, said Texas practice owner Roger Kendrick, DVM. “With the SediVue Dx analyzer, I am more confident that I’m getting an accurate understanding of a patient's health status and the potential of underlying disease.”
This Neural Network 4.0 update will be implemented across all existing SediVue Dx analyzers by the end of March.